Rush University Cancer Center Earns Reaccreditation

The Cancer Center recently earned a three-year reaccreditation from the Commission on Cancer

Cancer February 25, 2021
Melody Cobleigh, MD

The Rush University Cancer Center recently earned a three-year reaccreditation from the Commission on Cancer, a program of the American College of Surgeons dedicated to improving patient outcomes and quality of life through standard setting, research and education.

​The Commission on Cancer recognizes cancer programs that offer multidisciplinary, patient-centered treatments and address the full continuum of care, including prevention, survivorship and end-of-life ​care. To earn reaccreditation, the Cancer Center had to receive less than five findings after a rigorous survey earlier this month. Commission on Cancer facilities are evaluated every three years and must maintain levels of excellence in the delivery of comprehensive care. The next survey will be in 2024.​​​​

As one of more than 1,500 accredited institutions, Rush maintains a cancer registry and contributes data to the National Cancer Database. This database is the largest clinical disease registry in the world. Information from the database is used to explore trends in care, measure quality, monitor treatment patterns and enhance surveillance activities. Data is also used to create national, regional and state benchmark reports. 

The Rush University Cancer Center has proven its commitment to quality over the years with awards from various organizations, such as the American Society of Clinical Oncology, the Foundation for the Accreditation of Cellular Therapy, the National Pancreas Foundation and The Joint Commission. 

Related Stories